Clinical Trial Update: A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea) [Phase 1]

View source ↗

Summary

Phase 1 trial of OTS-412, a recombinant oncolytic vaccinia virus, in treatment-refractory solid tumor patients in South Korea; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• OTS-412

Snippet

Sponsor: Bionoxx Inc. | Conditions: Treatment-Refractory Solid Tumors | Phase 1 | Status: RECRUITING